AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2017
Nov 6, 2017
30016_dirs_2017-11-06_7ea182dc-b303-49a7-b479-85ef36a50c7b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2017-11-02
Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-02 | Common Stock | M | 12500 | $38.750 | Acquired | 1046573 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-11-02 | Non-Qualified Stock Option (right-to-buy) | $38.750 | M | 12500 | Disposed | 2018-02-13 | Common Stock (12500) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 98000 | Indirect |
Footnotes
F1: Includes 39 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 29, 2017.
F2: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F3: Not applicable.